4 articles
US premarket trading saw mixed results amid geopolitical tensions and corporate earnings. Notable movements included an oil tanker strike impacting energy sectors and Eli Lilly exploring an acquisitio
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion to access its lead psychedelic candidate BPL-003 for treatment-resistant depression. The deal marks Lilly's latest move into neuroscience
AtaiBeckley shares surged 50% premarket following reports that Eli Lilly is negotiating to acquire the psychedelic drug developer in a deal potentially exceeding $2 billion. The potential acquisition
Eli Lilly agreed to acquire biotech firm AtaiBeckley for $2.8 billion upfront plus potential milestones, expanding its neuroscience portfolio into the psychedelics market.
ChemBrief